Correction: Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study

Yasbanoo Moayedi¹, MD; Raghad Abdulmajeed², MHS; Juan Duero Posada¹, MD; Farid Foroutan¹, BSc; Ana Carolina Alba¹, MD, PhD; Joseph Cafazzo², PEng, PhD; Heather Joan Ross¹, MD, MHSc

¹Ted Rogers Centre of Excellence in Heart Function, University Health Network, Toronto, ON, Canada
²Centre for Global eHealth Innovation, Techna Institute, University Health Network, Toronto, ON, Canada

Corresponding Author:
Heather Joan Ross, MD, MHSc
Ted Rogers Centre of Excellence in Heart Function
University Health Network
Toronto General Hospital
190 Elizabeth St
Toronto, ON, M5G 2C4
Canada
Phone: 1 416 340 3482
Email: heather.ross@uhn.ca

Related Article:
Correction of: http://cardio.jmir.org/2017/2/e8/
(JMIR Cardio 2018;2(1):e10149) doi: 10.2196/10149

The authors of the paper “Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study” (Cardio JMIR 2017;1 (2): July-Dec) made a mistake by including a patient who had heart failure with preserved ejection fraction. This finding was just brought to the authors’ attention. They apologize for this oversight but have taken all measures to ensure that correct data is displayed in the article.

In the Introduction section, the following has been removed from the end of the final sentence:

...with reduced ejection fraction (HFrEF; ejection fraction <40%) anda NYHA Class II and III, as measured by daily steps by these two devices.

In the Methods section, the mention of “HFrEF” has been changed to “HF”. “HFrEF” has also been removed from the paper’s Abbreviations list.

In the Results section, the second and third sentences of the paragraph beginning with “Table 1...” has been changed to the following:

Patients were predominantly male (5/8, 63%), with an average age of 58 years and ischemic cardiomyopathy (5/8, 63%). All patients were on guideline-directed medical therapy including a betablocker and either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) when indicated.

Specifically, the text which was previously “(6/8, 75%)” now reads “(5/8, 63%)”. The average age was “57” and is now “58”, and the phrase “when indicated” has been added to the end of the latter sentence.

The caption for Table 1 has been shortened from “Demographics and baseline data of patients included in phase 2 of the study” to “Demographics and baseline data”. In Table 1 itself, data for Patient 7 has been changed under the following columns:

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Gender</th>
<th>LVEF</th>
<th>Etiology of HF</th>
<th>Medications, Betablocker</th>
<th>Medications, Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>58</td>
<td>Female</td>
<td>60</td>
<td>Familial</td>
<td>Carvedilol 12.5 mg</td>
<td>Ramipril 10 mg</td>
</tr>
</tbody>
</table>

The updated version of Table 1 is available below.

The corrected article will appear in the online version of the paper on the JMIR website on May 4, 2018, together with the publication of this correction notice. Because this was made after submission to PubMed, Pubmed Central, and other full-text repositories, the corrected article also has been re-submitted to those repositories.
Table 1. Demographics and baseline data.

<table>
<thead>
<tr>
<th>Number</th>
<th>Age (years)</th>
<th>Gender</th>
<th>LVEF(^a), %</th>
<th>Etiology of HF(^b)</th>
<th>NYHA(^c) class</th>
<th>Medications(^d)</th>
<th>Betablocker</th>
<th>Amiodarone</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67</td>
<td>Male</td>
<td>40</td>
<td>Ischemic</td>
<td>3</td>
<td>Bisoprolol 2.5 mg</td>
<td>None</td>
<td>Candesartan 8 mg</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>68</td>
<td>Male</td>
<td>18</td>
<td>Ischemic</td>
<td>2</td>
<td>Bisoprolol 10 mg</td>
<td>200</td>
<td>Irbesartan 300 mg</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>Male</td>
<td>25</td>
<td>Ischemic</td>
<td>3</td>
<td>Bisoprolol 10 mg</td>
<td>None</td>
<td>Perindopril 8 mg</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>61</td>
<td>Female</td>
<td>27</td>
<td>Non-ischemic</td>
<td>2</td>
<td>Bisoprolol 10 mg</td>
<td>None</td>
<td>Perindopril 4 mg</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>52</td>
<td>Male</td>
<td>25</td>
<td>Ischemic</td>
<td>2</td>
<td>Bisoprolol 10 mg</td>
<td>None</td>
<td>Perindopril 8 mg</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>57</td>
<td>Female</td>
<td>27</td>
<td>Non-ischemic</td>
<td>3</td>
<td>Carvedilol 25 mg</td>
<td>None</td>
<td>Ramipril 2.5 mg</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>Female</td>
<td>60</td>
<td>Familial</td>
<td>2</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>35</td>
<td>Male</td>
<td>33</td>
<td>Hypertrophic</td>
<td>3</td>
<td>Carvedilol 50 mg</td>
<td>None</td>
<td>Ramipril 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)LVEF: left ventricular ejection fraction.
\(^b\)HF: heart failure.
\(^c\)NYHA: New York Heart Association.
\(^d\)Drug doses are total daily dose.